ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $7 | $10 | $10 | $10 |
| Gross Profit | -$7 | -$10 | -$10 | -$10 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,779,275 | $3,208 | $5,408 | $2,124 |
| G&A Expenses | $7,357,559 | $11,213,201 | $7,605 | $5,580 |
| SG&A Expenses | $7,357,559 | $11,203 | $7,605 | $5,580 |
| Sales & Mktg Exp. | $0 | -$11,201,998 | $0 | $0 |
| Other Operating Expenses | -$9,127,704 | $0 | $810 | $0 |
| Operating Expenses | $9,130 | $14,410 | $13,823 | $7,704 |
| Operating Income | -$9,136,834 | -$14,421 | -$13,833 | -$7,704 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$283,346 | -$93,333 | -$1,035 | -$380 |
| Pre-Tax Income | -$9,420,180 | -$107,754 | -$14,868 | -$8,084 |
| Tax Expense | -$6,745 | -$9,456 | -$745 | $0 |
| Net Income | -$9,413,435 | -$98,298 | -$14,048 | -$8,084 |
| % Margin | – | – | – | – |
| EPS | -8.48 | -1,089.66 | -930.25 | -173.66 |
| % Growth | 99.2% | -17.1% | -435.7% | – |
| EPS Diluted | -8.48 | -1,089.66 | -930.25 | -173.66 |
| Weighted Avg Shares Out | 1,110 | 98 | 26 | 47 |
| Weighted Avg Shares Out Dil | 1,110 | 98 | 26 | 47 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $270 | $0 | $428 | $821 |
| Depreciation & Amortization | $7 | $10 | $10 | $10 |
| EBITDA | -$9,136,834 | -$107,743 | -$14,430 | -$7,252 |
| % Margin | – | – | – | – |